×
About 4,900 results

ALLMedicine™ Lyme Disease Center

Research & Reviews  1,472 results

Triangulating the New Frontier of Health Geo-Data: Assessing Tick-Borne Disease Risk as...
https://doi.org/10.3390/ijerph19159449
International Journal of Environmental Research and Publi... Maxwell SP, McNeely CL et. al.

Aug 13th, 2022 - Determining interventions to combat disease often requires complex analyses of spatial-temporal data to improve health outcomes. For some vulnerable populations, obtaining sufficient data for related analyses is especially difficult, thus exacerba...

Evaluation, Treatment, and Follow-up of Patients With Lyme Disease
https://clinicaltrials.gov/ct2/show/NCT00028080

Aug 12th, 2022 - Lyme disease is a multisystem illness caused by the spirochete Borrelia burgdorferi and it is the most common vector-borne illness in the United States. This protocol is designed to offer evaluation, therapy and follow up to patients with Lyme dis...

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
https://clinicaltrials.gov/ct2/show/NCT00001539

Aug 12th, 2022 - Lyme disease has emerged as the leading vector-borne disease in the United States. Despite how much has been learned about Lyme borreliosis in the past decade, there are still many remaining areas of uncertainty. One fundamental question is whethe...

Evaluation and Follow-up of People With Tick-borne Diseases
https://clinicaltrials.gov/ct2/show/NCT04318925

Aug 12th, 2022 - Lyme disease is a multisystem illness caused by the spirochete Borrelia burgdorferi and it is the most common vector-borne illness in the United States. Tick-borne disease cases reported to the Center for Disease Control and Prevention (CDC) have ...

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease
Pfizer Inc.

Aug 8th, 2022 - NEW YORK & SAINT-HERBLAIN, France--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NC...

see more →

Guidelines  8 results

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease
Pfizer Inc.

Aug 8th, 2022 - NEW YORK & SAINT-HERBLAIN, France--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NC...

Major test of first possible Lyme vaccine in 20 years begins
https://apnews.com/article/science-health-ticks-73fab8e29f3e2243c2db5bc33b3265e1
Associated Press; Neergaard L, Lum S.

Aug 8th, 2022 - DUNCANSVILLE, Pa. (AP) — Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years -- in hopes of better fighting the tick-borne threat.

Opinion du comité No 399 : Prise en charge des morsures de tiques et de la maladie de L...
https://doi.org/10.1016/j.jogc.2020.02.110
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Smith GN, Moore KM et. al.

May 18th, 2020 - Opinion du comité No 399 : Prise en charge des morsures de tiques et de la maladie de Lyme pendant la grossesse: (In English: Management of Tick Bites and Lyme Disease During Pregnancy).|2020|Smith GN,Moore KM,Hatchette TF,Nicholson J,Bowie W,|

Committee Opinion No. 399: Management of Tick Bites and Lyme Disease During Pregnancy.
https://doi.org/10.1016/j.jogc.2020.01.001
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Smith GN, Moore KM et. al.

May 18th, 2020 - Lyme disease is an emerging infection in Canada caused by the bacterium belonging to the Borrelia burgdorferi sensu lato species complex, which is transmitted via the bite of an infected blacklegged tick. Populations of blacklegged ticks continue ...

Global seroprevalence and sociodemographic characteristics of Borrelia burgdorferi sensu lato in human populations: a systematic review and meta-analysis
https://gh.bmj.com/content/7/6/e007744
BMJ Global Health; Dong Y, Zhou G et. al.

Lyme borreliosis (LB, also called Lyme disease) is caused by the tickborne spirochete Borrelia burgdorferi sensu lato (Bb). The complex biology and multiple immune escape mechanisms of LB make it the most common vectorborne disease in temperate No...

see more →

Drugs  53 results see all →

Clinicaltrials.gov  55 results

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
https://clinicaltrials.gov/ct2/show/NCT00001539

Aug 12th, 2022 - Lyme disease has emerged as the leading vector-borne disease in the United States. Despite how much has been learned about Lyme borreliosis in the past decade, there are still many remaining areas of uncertainty. One fundamental question is whethe...

Evaluation and Follow-up of People With Tick-borne Diseases
https://clinicaltrials.gov/ct2/show/NCT04318925

Aug 12th, 2022 - Lyme disease is a multisystem illness caused by the spirochete Borrelia burgdorferi and it is the most common vector-borne illness in the United States. Tick-borne disease cases reported to the Center for Disease Control and Prevention (CDC) have ...

Evaluation, Treatment, and Follow-up of Patients With Lyme Disease
https://clinicaltrials.gov/ct2/show/NCT00028080

Aug 12th, 2022 - Lyme disease is a multisystem illness caused by the spirochete Borrelia burgdorferi and it is the most common vector-borne illness in the United States. This protocol is designed to offer evaluation, therapy and follow up to patients with Lyme dis...

Major test of first possible Lyme vaccine in 20 years begins
https://apnews.com/article/science-health-ticks-73fab8e29f3e2243c2db5bc33b3265e1
Associated Press; Neergaard L, Lum S.

Aug 8th, 2022 - DUNCANSVILLE, Pa. (AP) — Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years -- in hopes of better fighting the tick-borne threat.

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease
Pfizer Inc.

Aug 8th, 2022 - NEW YORK & SAINT-HERBLAIN, France--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NC...

see more →

News  353 results

Climate Change Puts Lyme Disease in Focus for France's Valneva After COVID Blow
https://www.medscape.com/viewarticle/978788

Aug 10th, 2022 - LONDON (Reuters) - With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot. Although Valneva secured European Union and British regu...

Pfizer Begins Trial for Lyme Disease Vaccine
https://www.medscape.com/viewarticle/978936

Aug 9th, 2022 - Pfizer has launched a late-stage clinical trial to test a vaccine that could protect against Lyme disease, the company announced Monday. If the trial succeeds, the vaccine could be the first human vaccine for the tick-borne illness in the U.S. in ...

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease
Pfizer Inc.

Aug 8th, 2022 - NEW YORK & SAINT-HERBLAIN, France--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NC...

Major test of first possible Lyme vaccine in 20 years begins
https://apnews.com/article/science-health-ticks-73fab8e29f3e2243c2db5bc33b3265e1
Associated Press; Neergaard L, Lum S.

Aug 8th, 2022 - DUNCANSVILLE, Pa. (AP) — Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years -- in hopes of better fighting the tick-borne threat.

Insurance Data Shows Big Rise in Lyme Disease in US
https://www.medscape.com/viewarticle/978564

Aug 3rd, 2022 - Lyme disease diagnoses have increased dramatically in the U.S. during the past 15 years, rising 357% in rural areas and 65% in urban areas, according to new data released by FAIR Health. The trends show that tick-borne illnesses are becoming a mor...

see more →

Patient Education  19 results see all →